| Name | CYP3A |
|---|---|
| Synonyms | CP33; CYP3; HLP; CYP3A; CP34; CYP 3A4; CYP 3; CYP3A3… |
| Name | biphenyl |
|---|---|
| CAS | 1,1′-biphenyl |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19303460 | Verreault J, Letcher RJ, Sonne C, Dietz R: In vitro metabolism of polychlorinated biphenyls and cytochrome P450 monooxygenase activities in dietary-exposed Greenland sledge dogs. Comp Biochem Physiol C Toxicol Pharmacol. 2009 Jul;150(1):91-100. Epub 2009 Mar 19. The in vitro metabolism of a polychlorinated biphenyl (PCB) mixture was examined using hepatic microsomes of dietary-exposed Greenland sledge dogs (Canis familiaris) to an organohalogen-rich diet (Greenland minke whale blubber: EXP cohort) or a control diet (pork fat: CON cohort). Based on documented hepatic microsomal CYP isoenzyme substrate specificities in canines, present associations suggest that primarily CYP2B/2C and CYP3A were inducible in sledge dogs and responsible for the in vitro metabolism of PCB-18 and -33. |
1(0,0,0,1) | Details |
| 18720339 | Pinto-Bazurco Mendieta MA, Negri M, Hu Q, Hille UE, Jagusch C, Jahn-Hoffmann K, Muller-Vieira U, Schmidt D, Lauterbach T, Hartmann RW: CYP17 inhibitors. Arch Pharm. 2008 Oct;341(10):597-609. Compound 21 showed only weak inhibition of CYP3A4 (32 and 64% at 2 and 10 microM, respectively). |
1(0,0,0,1) | Details |
| 19211174 | Hille UE, Hu Q, Vock C, Negri M, Bartels M, Muller-Vieira U, Lauterbach T, Hartmann RW: Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and -substituted methyleneimidazolyl biphenyls. Eur J Med Chem. 2009 Jul;44(7):2765-75. Epub 2009 Jan 19. Promising compounds were further tested for their selectivity against the hepatic enzyme CYP3A4 and the glucocorticoid-forming enzyme CYP11B1. |
1(0,0,0,1) | Details |
| 18672868 | Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Muller-Vieira U, Lauterbach T, Hartmann RW: Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J Med Chem. 2008 Aug 28;51(16):5009-18. Epub 2008 Aug 2. Promising compounds were further evaluated for selectivity against CYP11B1, CYP11B2, and the hepatic CYP3A4. |
1(0,0,0,1) | Details |
| 18801310 | Tan W, Chen H, Zhao J, Hu J, Li Y: A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability. J Pharm Pharm Sci. 2008;11(3):97-105. PURPOSE: To determine the possible mechanism of poor bioavailability of bicyclol, and clarify the respective contribution of P- glycoprotein (P-gp) and Cytochrome 3A (CYP3A). |
4(0,0,0,4) | Details |
| 19343062 | Zeng Y, He YJ, He FY, Fan L, Zhou HH: Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacol Sin. 2009 Apr;30(4):478-84. AIM: To evaluate the potential drug-drug interactions between bifendate and cyclosporine, a substrate of CYP3A4, in relation to different CYP3A4*18B genotype groups. |
2(0,0,0,2) | Details |